Identification of CDK5RAP2 as a causative gene of focal epilepsy without microcephaly.

Seizure

Department of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, China. Electronic address:

Published: August 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: The CDK5RAP2 gene, which encodes a regulator of cyclin-dependent kinase activity, plays a vital role in brain development. CDK5RAP2 variants have been previously reported in patients with primary microcephaly-3, with or without epilepsy. This study aimed to investigate the association between CDK5RAP2 and epilepsy.

Method: Trio-based whole-exome sequencing was performed in patients with idiopathic focal epilepsy without acquired causes. Sub-regional effects, genotype-phenotype correlation, and protein-protein interactions were analysed to reveal gene-disease association.

Results: Four compound heterozygous CDK5RAP2 variants were identified in four unrelated cases. These variants had no or extremely low allele frequencies in the controls and showed statistically higher frequencies than those in the controls. These variants were predicted to have changes in hydrogen bonds, decreased protein stability, and significant alterations in the hydrophobicity. All patients had focal epilepsy without microcephaly. Patient in one case with two variants of paired missense variants located at the functional domain showed refractory seizures, whereas another patient with variants outside functional domains was seizure-free, suggesting a potential sub-regional effect. The proportion of missense variants in the epilepsy group was significantly higher than that in the primary microcephaly group, suggesting a potential genotype-phenotype correlation. Protein-protein interaction analysis showed that CDK5RAP2 interacted with 31 proteins with high confidence, of which 13 genes were associated with epilepsy and neurodevelopmental disorders, suggesting a potential association between CDK5RAP2 and epilepsy.

Conclusion: CDK5RAP2 is a novel causative gene for focal epilepsy without microcephaly.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.seizure.2025.08.018DOI Listing

Publication Analysis

Top Keywords

focal epilepsy
16
epilepsy microcephaly
12
suggesting potential
12
causative gene
8
gene focal
8
variants
8
cdk5rap2 variants
8
association cdk5rap2
8
genotype-phenotype correlation
8
correlation protein-protein
8

Similar Publications

Analysis of six CYP450 genetic variants regarding the response to cannabidiol combined with anticonvulsant medication in mexican patients with drug-resistant epilepsy.

Front Pharmacol

August 2025

Unidad de Investigación Médica en Enfermedades Neurológicas, Hospital de Especialidades, "Dr. Bernardo Sepúlveda", Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, Mexico.

Background: Cannabidiol (CBD) reduces the frequency of seizures in individuals with specific epileptic syndromes, but its effectiveness for other types of drug-resistant epilepsy (DRE) is unclear. CYP450 enzymes primarily metabolize CBD. The aim of this study was to identify CYP450 genotypes regarding the response of CBD treatment concomitant with anti-seizure drugs in patients with DRE.

View Article and Find Full Text PDF

Understanding the cognitive trajectory of a neurological disease can provide important insight on underlying mechanisms and disease progression. Cognitive impairment is now well established as beginning many years before the diagnosis of Alzheimer's disease, but pre-diagnostic profiles are unclear for other neurological conditions that may be associated with cognitive impairment. We analysed data from the prospective UK Biobank cohort with study baseline assessment performed between 2006 and 2010 and participants followed until 2021.

View Article and Find Full Text PDF

ObjectivesThe objective of this study was to evaluate the occurrence of voltage-gated potassium channel (VGKC) antibodies and the pattern of MRI changes in cats with complex partial seizures with orofacial involvement (CPSOFI), as well as to investigate whether there are factors influencing survival that could be used as prognostic markers in those cats.MethodsCats with CPSOFI were identified retrospectively. The following data were retrieved from the hospital database: signalment, age at first seizure and presentation, the presence of antibodies against VGKC (leucine-rich glioma inactivating factor 1 (LGI1), contactin-associated protein 2 (CASPR2)) and cerebrospinal fluid (CSF) analysis findings.

View Article and Find Full Text PDF

Laser Interstitial Thermal Therapy (LITT) in pediatric neurosurgery: Single center retrospective analysis of 41 consecutive procedures.

Neurochirurgie

September 2025

Necker Hospital, Departments of Pediatric Neurosurgery, Radiology, Pediatric Neurology and Anesthesiology; Reference Center for Rare Epilepsies CRéER, Member of ERN Epicare; APHP, Paris, France; Université de Paris Cité, Paris, France; Institut Imagine, INSERM U1163, Paris, France; Paris Kids Can

Introduction: Laser Interstitial Thermal Therapy under MRI control has emerged as a safe and efficient alternative to microsurgery in epilepsy and neurooncology procedures. Yet it has been used only recently in seldom European centers. Here, we report our 4 years' experience with LITT in children (complications, epileptic and oncologic outcomes).

View Article and Find Full Text PDF

Objectives: Responsive neurostimulation (RNS) electrocorticographic (ECoG) data may have a role in objectively assessing the efficacy of add-on antiseizure medications (ASMs). This retrospective, multicenter, observational, 24-week study is the first to report the effects of cenobamate on RNS-detected events (RDE).

Methods: Patients included adults (≥18 years) with a history of recurrent focal seizures and implanted RNS who initiated adjunctive cenobamate ≥ 3 months after RNS implant between 4/1/20-12/15/23 and who received ≥ 2 weeks of cenobamate (≥50 mg/day).

View Article and Find Full Text PDF